Biotechs tend to start rising when PDUFA dates are announced and then eventually fall when the drug gets approved (because then they have to show they can actually sell the drug). Obviously Cytodyn has other catalysts that could affect the stock in the time between when the company announces a PDUFA date and an HIV approval but that's the way it generally goes.